Table III.

Long non-coding RNA identified to be associated with promoter methylation and clinical outcomes.

Author, year	Gene	Status	Function	(Refs.)
Yang et al, 2012	H19	Increased	Cellular proliferation, p53 inactivation	(78)
Xu et al, 2013	HOTAIR	Increased	Poor OS, invasiveness	(79)
Yang et al, 2014	GHET1	Increased	Tumor size, tumor invasion and poor survival	(80)
Lee et al, 2014	nc886	Decreased	Poor survival	(81)
Xu et al, 2014	FENDRR	Decreased	Tumor invasion, stage, lymph node metastasis, poor prognosis	(82)
Han et al, 2014	LEIGC	Decreased	Tumor growth, cell proliferation, 5-FU sensitivity	(83)
Okugawa et al, 2014	MALAT1	Increased	Peritoneal dissemination	(84)
Xu et al, 2014	LSINCT5	Increased	Tumor size, depth, stage, worse DFS and DSS	(85)

H19, H19 imprinted maternally expressed transcript; HOTAIR, HOX transcript antisense RNA; OS, overall survival; GHET1, gastric carcinoma proliferation enhancing transcript 1; nc886, vault RNA 2; FENDRR, FOXF1 adjacent non-coding developmental regulatory RNA; LEIGC, lower expression in gastric cancer; 5-FU, 5-fluorouracil; MALAT1, metastasis-associated lung adenocarcinoma transcript 1; LSINCT5, long stress-induced non-coding transcript 5; DFS, disease-free survival; DSS, disease-specific survival.